Pandemik SARS-COV-2 enfeksiyonu geçiren hastalarda mirna araştırılması
Yükleniyor...
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: SARS-CoV-2’nin konak bağışık yanıtını tetiklediği ve buna bağlı olarak semptomlara neden olduğu bilinmektedir. Özellikle gen ekspresyonunu ve protein fonksiyonunu düzenlemede etkili miRNA'lar, viral hastalıklarda rol almaktadır. MiRNA (miR) ekpresyonundaki değişiklikler hedef proteinlerin yapısında ve işlevlerinde değişikliklere neden olarak hastalıkların patogenezine katkıda bulunabilmektedir. Çalışmamızın amacı, SARS-COV-2 ile enfekte hastaları sağlıklı kontrol grubuyla karşılaştırarak miR-19a-3p, miR19b-3p, miR-21, miR-26a-5p, miR-146a, miR-let-7b-3p, miR-155, miR-16, miR-590, miR-1307-3p serum düzeylerini ölçerek klinik tabloyla ilişkisini belirlemektir.
Yöntem: Çalışmaya PZR yöntemi ile COVID-19 tanısı konan 70 hasta ve herhangi bir hastalığı olmayan 30 kontrol grubunun kan örnekleri dahil edildi. Hastalar hafif, orta, ağır olmak üzere üç gruba ayrıldı. MiRNA izolasyonu amacıyla SanPrep Column MicroRNA Mini-Prep kiti (Bio Basic Inc., Toronto, Kanada) kullanıldı. Daha sonra miRNA’dan cDNA elde edilmesi miRNA All-In-One cDNA Synthesis kit (Applied Biological Materials (ABM) Inc., Richmond, Kanada) ticari kiti ile gerçekleştirildi. MiRNA seviye ölçümleri ise real time PZR kiti (ABM Inc., Richmond, Kanada) ile yapıldı. Relatif ekspresyonların hesaplanmasında Livak'ın ΔΔCT metodu kullanılarak 2(–ΔΔCT) değerleri hesaplandı.
Bulgular: MiR-1307-3p, miR-146, miR-26a-5p, miR-21, miR-19a-3p, miR19b-3p, miR-let-7b-3p’nin serum ekspresyon düzeyleri COVID-19 hastalarında daha yüksek tespit edildi. COVID-19 hastalarında miR-1307-3p, miR-146, miR-26a-5p, miR-21, miR19b-3p, miR-let-7b-3p istatistiksel olarak anlamlıydı (p<0.05). MiR-16’da aşağı regülasyon gözlendi. Hasta grupları arasında miR ekspresyon düzeyleri farklılık gösterdi.
Sonuç: Konak-virüs etkileşimleri göz önüne alındığında, miRNA’ların COVID-19’da hem terapötik hedef olabileceğini hem de hastalığın patogenezini anlamaya yardımcı olacağını düşünüyoruz. Hastalığın patogenezinin anlaşılmasında in vivo ve in vitro deneyler ile birlikte klinik çalışmalarının yapılması önem arz etmektedir.
Objective: It is known that SARS-CoV-2 triggers the host immune response and accordingly causes symptoms. In particular, miRNAs that are effective in regulating gene expression and protein function play a role in viral diseases. Changes in miRNA (miR) expression may contribute to the pathogenesis of diseases by causing changes in the structure and functions of target proteins. The aim of our study was to compare the patients infected with SARS-COV-2 with the healthy control group and compare miR-19a-3p, miR19b-3p, miR-21, miR-26a-5p, miR-146a, miR-let-7b-3p, miR-155, miR-16, miR-590, miR-1307-3p. To determine the effect on the clinical correlation by measuring the serum levels of this miRNAs. Methods: Blood samples of 70 patients diagnosed with COVID-19 by PCR method and 30 control groups without any disease were included in the study. The patients were divided into three groups as mild, moderate and severe. SanPrep Column MicroRNA Mini-Prep kit (Bio Basic Inc., Toronto, Canada) was used for miRNA isolation. Extraction of cDNA from miRNA was performed with the commercial kit of the miRNA All-In-One cDNA Synthesis kit (Applied Biological Materials (ABM) Inc., Richmond, Canada). MiRNA level measurements were made with real time PCR kit (ABM Inc., Richmond, Canada). 2(–ΔΔCT) values were calculated using Livak's ΔΔCT method to calculate the relative expressions. Results: Serum expression levels of miR-1307-3p, miR-146, miR-26a-5p, miR-21, miR-19a-3p, miR19b-3p, miR-let-7b-3p were higher in COVID-19 patients detected. MiR-1307-3p, miR-146, miR-26a-5p, miR-21, miR19b-3p, miR-let-7b-3p were statistically significant in COVID-19 patients (p<0.05). Downregulation was observed in miR-16 MiR expression levels were different between patient groups. Conclusion: Considering host-virus interactions, we think miRNAs may be both a therapeutic target in COVID-19 and help to understand the pathogenesis of the disease. In understanding the pathogenesis of the disease, it is important to carry out clinical studies together with in vivo and in vitro experiments.
Objective: It is known that SARS-CoV-2 triggers the host immune response and accordingly causes symptoms. In particular, miRNAs that are effective in regulating gene expression and protein function play a role in viral diseases. Changes in miRNA (miR) expression may contribute to the pathogenesis of diseases by causing changes in the structure and functions of target proteins. The aim of our study was to compare the patients infected with SARS-COV-2 with the healthy control group and compare miR-19a-3p, miR19b-3p, miR-21, miR-26a-5p, miR-146a, miR-let-7b-3p, miR-155, miR-16, miR-590, miR-1307-3p. To determine the effect on the clinical correlation by measuring the serum levels of this miRNAs. Methods: Blood samples of 70 patients diagnosed with COVID-19 by PCR method and 30 control groups without any disease were included in the study. The patients were divided into three groups as mild, moderate and severe. SanPrep Column MicroRNA Mini-Prep kit (Bio Basic Inc., Toronto, Canada) was used for miRNA isolation. Extraction of cDNA from miRNA was performed with the commercial kit of the miRNA All-In-One cDNA Synthesis kit (Applied Biological Materials (ABM) Inc., Richmond, Canada). MiRNA level measurements were made with real time PCR kit (ABM Inc., Richmond, Canada). 2(–ΔΔCT) values were calculated using Livak's ΔΔCT method to calculate the relative expressions. Results: Serum expression levels of miR-1307-3p, miR-146, miR-26a-5p, miR-21, miR-19a-3p, miR19b-3p, miR-let-7b-3p were higher in COVID-19 patients detected. MiR-1307-3p, miR-146, miR-26a-5p, miR-21, miR19b-3p, miR-let-7b-3p were statistically significant in COVID-19 patients (p<0.05). Downregulation was observed in miR-16 MiR expression levels were different between patient groups. Conclusion: Considering host-virus interactions, we think miRNAs may be both a therapeutic target in COVID-19 and help to understand the pathogenesis of the disease. In understanding the pathogenesis of the disease, it is important to carry out clinical studies together with in vivo and in vitro experiments.
Açıklama
Anahtar Kelimeler
COVID-19, miR-146, miR-26a-5p, miR-21, miR-let-7b-3p, co
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Arslan, G. K. (2023). Pandemik SARS-COV-2 enfeksiyonu geçiren hastalarda mirna araştırılması. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Temel Tıp Bilimleri Bölümü Tıbbi Mikrobiyoloji Anabilim Dalı, Konya.
